Learn more about the benefits of OptoWire® as a workhorse wire at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference by visiting Opsens at their booth (#1907) or attend the complimentary educational lunch symposium. RSVP Now! Educational Lunch Symposium “FFR and Non-Hyperemic Pressure Ratios: Start Right, Finish […]
Category: News & Events
OPSENS REPORTS Q3 2018 RESULTS – Quarterly Revenues Eclipse $6.4 M
Quebec City, Quebec, July 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter ended May 31, 2018. Highlights for the quarter Consolidated revenues reached $6,398,000 for the three-month period compared […]
VISIT OPSENS AT THE CARDIOVASCULAR INNOVATIONS 2018 CONFERENCE
Learn more about the benefits of OptoWire® as a workhorse wire at the Cardiovascular Innovations (CVI) 2018 Conference by visiting us at the Opsens booth (#T4) or attend the complimentary educational lunch symposium with live case transmission sponsored by Opsens. RSVP […]
VISIT OPSENS AT THE 14TH ANNUAL C3 CONFERENCE
Learn more about the benefits of OptoWire as a workhorse wire at the 14th annual Complex Cardiovascular Catheter Therapeutics: Advanced Endovascular and Coronary Intervention Global Summit (C3) conference by visiting us at the Opsens booth #207 or attend the complimentary educational lunch […]
OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS
Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically […]
OPSENS REPORTS Q2 2018 RESULTS – CONSOLIDATED PRODUCT SALES UP 44%
Quebec City, Quebec, April 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2018. Highlights Consolidated product sales reached $5,352,000 compared with $3,710,000 for the same period […]
OPSENS’ TECHNOLOGY GRANTED FDA APPROVAL IN ABIOMED’S IMPELLA CARDIAC PUMP®
Quebec City, Quebec, April 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces that the integration of Opsens’ technology, within the Impella Cardiac Pump® (“Impella CP®“), marketed by its client Abiomed, Inc. (” Abiomed “), is approved […]
84th German Cardiac Society Annual Meeting in Mannheim 2018
Opsens sponsored Symposium: Clinical value of FFR and adenosine-free alternatives in the cathlab Our Distributor, Bisping Medizintechnik GmbH will showcase the Opsens technology at German Cardiac Societies Annual Meeting in Mannheim, Germany, from April 4th to 7th, 2018. They will […]
VISIT OPSENS MEDICAL AT SCAI 2018
Learn more about the benefits of OptoWire as a workhorse wire at the Society for Cardiovascular Angiography and Interventions – SCAI 2018 by visiting us at the Opsens booth (#603) or joining us at one of the following: Attend the […]
SIF 2018 – OPSENS MEDICAL ON EXHIBIT! March 21-24, 2018
Hear, see and feel the OptoWire® Deux difference at SIF 2018 in Scottsdale, Arizona. Visit the Opsens Medical booth to meet the experts, experience an OptoWire demonstration, and learn more about The OptoWire® One-Wire PCI™ Program! […]
